Cohere Acquires Reliant AI to Build a Biopharma-Native Platform 🔗

Cohere has acquired Reliant AI, a Montreal and Berlin-based company that built AI tools specifically for life science analysts, covering literature reviews, clinical trial data analysis, and research workflows. Clients include GSK and Ipsen Pharma. The 35-person team integrates into Cohere, with co-founders Karl Moritz Hermann and Marc Bellemare stepping into vice-president roles. The acquisition follows Cohere's merger with Aleph Alpha and signals a deliberate push to adapt its North platform for regulated industries. Chief AI officer Joelle Pineau framed the deal as acquiring established credibility and domain expertise in a market where OpenAI and Anthropic are competing for the same enterprise contracts.

QIAGEN and NVIDIA Partner to Bring BioNeMo Into Drug Discovery 🔗

Announced at BIO-IT World, QIAGEN and NVIDIA have formed a partnership to integrate NVIDIA's BioNeMo platform and advanced computing capabilities into QIAGEN Digital Insights. The collaboration applies graph-based AI to QIAGEN's curated biomedical knowledge base, targeting target identification, biomarker discovery, and data analysis throughout the drug development process. Initial pilot programs will roll out to select pharmaceutical and biotech partners before broader implementation.

Ennov Secures Growth Investment to Accelerate AI in Life Sciences Compliance 🔗
Ennov, a Paris-based provider of regulatory, quality, clinical, and pharmacovigilance software, has secured a growth investment from Bregal Sagemount and Ardian. The company serves approximately 650 clients with over 500,000 users across 30 countries. The investment will fund AI development toward what Ennov describes as agentic workflows, including autonomous regulatory document classification, compliance monitoring, and document drafting. CEO Olivier Pâris framed the ambition as replacing disconnected legacy compliance systems with an integrated AI-driven platform, explicitly positioning against Veeva Systems and IQVIA.

The signal: With regulatory complexity growing globally and the demand for traceable AI in GxP environments intensifying, the compliance software category is attracting serious growth capital. Vendors who can embed agentic AI into validated regulatory workflows have a structural advantage, and institutional investors are beginning to act on that thesis. The Ennov deal is the third compliance-layer investment we have tracked in under two months.

Opentrons Brings 21 CFR Part 11 Compliance to Affordable Lab Automation 🔗

Opentrons Labworks unveiled Compliance Ready Software for the Opentrons Flex robotic platform at SLAS Europe 2026. The software introduces FDA 21 CFR Part 11-aligned authentication, signed audit trails, and role-based access at a cost structure significantly lower than traditional GxP automation systems. It targets non-GMP regulated environments — pharmaceutical research and medical device development — where labs need to automate without the overhead of enterprise compliance platforms.

The signal: The governance problem in life sciences AI does not stop at the enterprise layer. It runs to the bench. As agents are deployed at scale across CROs and pharma operations, the same audit-trail requirement is arriving in research labs. Opentrons is betting that accessible compliance infrastructure at the lab automation level is a real product gap. The fact that it is launching this at SLAS, not a regulatory conference, tells you where the demand is coming from.